Editas Medicine, Inc. (NASDAQ:EDIT) reported Q2 2017 earnings this Afternoon, coming in at ($0.65) per share, missing Wall Street’s estimates of ($0.57) per Share. Revenue for the quarter came in at $3.10 million beating analyst estimates of $2.20 million
Analyst Coverage For Editas Medicine, Inc. (NASDAQ:EDIT)
These are 4 Hold Ratings, 3 Buy Ratings .
The current consensus rating for Editas Medicine, Inc. (NASDAQ:EDIT) is Hold (Score: 2.43) with a consensus target price of $28.00 , a potential (55.73% upside)Recent Insider Trading for Editas Medicine, Inc. (NASDAQ:EDIT)
- On 6/2/2017 Boris Nikolic, Director, bought 35,000 with an average share price of $14.07 per share and the total transaction amounting to $492,450.00.
- On 6/2/2017 Gerald Frank Cox, Insider, bought 4,000 with an average share price of $14.15 per share and the total transaction amounting to $56,600.00.
- On 5/22/2017 Kevin Bitterman, Director, sold 1,000,000 with an average share price of $17.00 per share and the total transaction amounting to $17,000,000.00.
- On 3/15/2017 Alexandra Glucksmann, COO, sold 1,000 with an average share price of $26.41 per share and the total transaction amounting to $26,410.00.
- On 2/15/2017 Alexandra Glucksmann, COO, sold 6,000 with an average share price of $20.58 per share and the total transaction amounting to $123,480.00.
- On 2/15/2017 Andrew A F Hack, CFO, sold 3,000 with an average share price of $19.20 per share and the total transaction amounting to $57,600.00.
Recent Trading for Editas Medicine, Inc. (NASDAQ:EDIT) Shares of Editas Medicine, Inc. closed the previous trading session at 17.98 down -0.88 -4.67% with 857,673 shares trading hands.